

Recurrent somatic alterations of *FGFR1* and *NTRK2* in pilocytic astrocytoma

David T W Jones^{1,39}, Barbara Hutter^{2,39}, Natalie Jäger^{2,39}, Andrey Korshunov^{3,4}, Marcel Kool¹, Hans-Jörg Warnatz⁵, Thomas Zichner⁶, Sally R Lambert⁷, Marina Ryzhova⁸, Dong Anh Khuong Quang⁹, Adam M Fontebasso⁹, Adrian M Stütz⁶, Sonja Hutter¹, Marc Zuckermann¹⁰, Dominik Sturm¹, Jan Gronych¹⁰, Bärbel Lasitschka¹¹, Sabine Schmidt¹¹, Huriye Şeker-Cin¹, Hendrik Witt^{1,12}, Marc Sultan⁵, Meryem Ralser⁵, Paul A Northcott¹, Volker Hovestadt¹⁰, Sebastian Bender¹, Elke Pfaff¹, Sebastian Stark¹, Damien Faury⁹, Jeremy Schwartzentruber¹³, Jacek Majewski¹³, Ursula D Weber¹⁰, Marc Zapatka¹⁰, Benjamin Raeder⁶, Matthias Schlesner², Catherine L Worth⁵, Cynthia C Bartholomae¹⁴, Christof von Kalle^{14,15}, Charles D Imbusch², Sylwester Radomski^{2,16,17}, Chris Lawerenz², Peter van Sluis¹⁸, Jan Koster¹⁸, Richard Volckmann¹⁸, Rogier Versteeg¹⁸, Hans Lehrach⁵, Camelia Monoranu¹⁹, Beate Winkler²⁰, Andreas Unterberg²¹, Christel Herold-Mende²¹, Till Milde^{12,22}, Andreas E Kulozik¹², Martin Ebinger²³, Martin U Schuhmann²⁴, Yoon-Jae Cho²⁵, Scott L Pomeroy^{26,27}, Andreas von Deimling^{3,4}, Olaf Witt^{12,22}, Michael D Taylor^{28,29}, Stephan Wolf¹¹, Matthias A Karajannis³⁰, Charles G Eberhart³¹, Wolfram Scheurlen³², Martin Hasselblatt³³, Keith L Ligon^{26,34,35}, Mark W Kieran^{26,36}, Jan O Korbel⁶, Marie-Laure Yaspo⁵, Benedikt Brors², Jörg Felsberg³⁷, Guido Reifenberger³⁷, V Peter Collins⁷, Nada Jabado^{9,38}, Roland Eils^{2,15-17,40}, Peter Lichter^{10,15,40} & Stefan M Pfister^{1,12,40}, for the International Cancer Genome Consortium PedBrain Tumor Project

Pilocytic astrocytoma, the most common childhood brain tumor¹, is typically associated with mitogen-activated protein kinase (MAPK) pathway alterations². Surgically inaccessible midline tumors are therapeutically challenging, showing sustained tendency for progression³ and often becoming a chronic disease with substantial morbidities⁴. Here we describe whole-genome sequencing of 96 pilocytic astrocytomas, with matched RNA sequencing ($n = 73$), conducted by the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. We identified recurrent activating mutations in *FGFR1* and *PTPN11* and new *NTRK2* fusion genes in non-cerebellar tumors. New *BRAF*-activating changes were also observed. MAPK pathway alterations affected all tumors analyzed, with no other significant mutations identified, indicating that pilocytic astrocytoma is predominantly a single-pathway disease. Notably, we identified the same *FGFR1* mutations in a subset of *H3F3A*-mutated pediatric glioblastoma with additional alterations in the *NF1* gene⁵. Our findings thus identify new potential therapeutic targets in distinct subsets of pilocytic astrocytoma and childhood glioblastoma.

Pilocytic astrocytoma is the most common central nervous system (CNS) neoplasm in childhood, accounting for ~20% of all pediatric brain tumors. Tumor locations in our cohort reflect the

fact that pilocytic astrocytomas occur throughout the CNS, with about half arising outside the cerebellum (**Supplementary Fig. 1**). Extracerebellar tumors are often surgically inaccessible, leading to chronic disease with multiple recurrences, visual and neurological impairment and/or side-effects of therapy^{1,4}. Genetic alterations within the MAPK signaling pathway are a hallmark of this tumor, with *KIAA1549-BRAF* fusion being the most frequent event⁶⁻⁸. A smaller number of tumors harbor *BRAF* or *KRAS* point mutations, alternative *BRAF-RAF1* fusions or germline *NF1* mutations². Pilocytic astrocytoma has therefore been hypothesized to represent a single-pathway disease². Previously, however, no MAPK pathway changes were identifiable in 15–20% of tumors (mostly non-cerebellar)².

To investigate the full range of genetic alterations in pilocytic astrocytoma, we performed whole-genome sequencing of tumor and blood DNA from 96 affected individuals (**Supplementary Table 1**). Corresponding RNA sequencing data and data from mate-pair sequencing with larger inserts (for enhanced detection of structural rearrangements) were generated for 73 and 68 samples, respectively. The average somatic mutation rate was extremely low (<0.1 mutation per megabase), with a mean of 1.6 nonsynonymous single-nucleotide variants (SNVs) per tumor (range of 0–9; **Supplementary Table 1**), similar to the rate described in *NF1*-associated pilocytic astrocytomas⁹. The somatic mutation rate in our series was markedly lower than those recently reported for the malignant pediatric brain tumor

A full list of author affiliations appears at the end of the paper.


Received 26 March; accepted 3 June; published online 30 June 2013; doi:10.1038/ng.2682

Figure 1 New *BRAF* alterations in pilocytic astrocytoma. (a) Schematic of the *RNF130-BRAF* fusion gene in ICGC_PA112 resulting from a translocation between chromosomes 5 and 7. A similar fusion was observed in ICGC_PA96. The cDNA sequence at the fusion breakpoint (dashed line) and resulting exon and protein structures are shown. A reciprocal fusion between *RUFY1* (encoding RUN and FYVE domain-containing 1) and *TMEM178B* (encoding transmembrane protein 178B) on the derivative chromosome 5 in ICGC_PA112 was also found to be expressed in RNA sequencing analysis (data not shown).

RPM, reads per million; KD, kinase domain.

(b) Computational modeling of two *BRAF* monomers (light and dark gray) with a ValLeuArg insertion (blue and magenta) between Arg506 and Lys507 (green), as identified in ICGC_PA65 (p.Arg506insValLeuArg, insVLR). Protein Data Bank (PDB) structure 4E26 was used as a template. Val600, a mutational hotspot, is shown in yellow. A new dimer interface is formed between the protomers, with hydrogen bonds formed between the new arginine side chains (dashed lines) and a hydrophobic interaction between the leucine side chains (magenta).

(c) Protein blot analysis of NIH3T3 cells transfected with empty vector (EV) or with vector expressing wild-type (WT) *BRAF*, *BRAF*^{V600E} or *BRAF*^{insVLR}. The newly identified *BRAF*^{insVLR} mutant results in greater phosphorylation of ERK1 and ERK2 (pERK1/2), with phosphorylation at a similar level to that seen with the known oncogenic *BRAF*^{V600E} form. (d) Pulldown assay with immunoprecipitation (IP) of HA-tagged *BRAF*^{insVLR}, showing that this new mutant forms homodimers with coexpressed AU1-tagged *BRAF*^{insVLR} mutant but does not seem to form a strong heterodimer with wild-type *BRAF*.



medulloblastoma^{10–12} and for several other pediatric solid tumors¹³. The average number of small insertion-deletion alterations (indels) affecting coding sequences was <1 per case. All coding somatic SNVs and indels are listed in **Supplementary Table 2**.

In line with other tumor types^{10,14,15}, pilocytic astrocytomas had genome-wide mutation rates that positively correlated with the age of the affected individual ($r = 0.42$; $P = 2.3 \times 10^{-5}$, Pearson's product-moment correlation; **Supplementary Fig. 2a**). The observed mutations were predominantly cytosine-to-thymine transitions at CpG sites (likely arising from deamination of methylated cytosines), suggesting that the age-dependent increase in mutation frequency may largely be due to background processes occurring in progenitor cells before tumorigenesis, as recently reported in leukemia¹⁵ (**Supplementary Fig. 2b**).

Most of the known events activating the MAPK pathway were also found in our series, including *KIAA1549-BRAF* fusion variants (70 cases), a *FAM131B-BRAF* fusion¹⁶, 4 *BRAF*^{V600E} mutations and 1 *BRAF*^{ins599T} alteration (**Supplementary Table 1**). Three tumors were associated with neurofibromatosis type 1. This prevalence is lower than would be expected for prospective cohorts (5–10%), as material for biological studies from these typically optic pathway-associated tumors is limited. *NF1* has been reported to follow a classical tumor suppressor model in pilocytic astrocytoma, with a somatic second hit in addition to a germline alteration⁹. This model also held true in our series (**Supplementary Table 1**).

Analysis of copy number and structural alterations using DNA and RNA sequencing identified four new *BRAF* fusions (**Fig. 1** and **Supplementary Fig. 3**). As expected, all variants resulted in loss of the N-terminal regulatory region of *BRAF*. An *RNF130-BRAF* fusion derived from a reciprocal t(5;7)(q35;q34) translocation was seen in two cases (**Fig. 1a**), with single examples identified of *CLCN6-BRAF*, *MKRN1-BRAF* and *GNAI1-BRAF* fusions (**Supplementary Fig. 3a–c**). Thus, non-*KIAA1549-BRAF* fusions comprise a notable minority of activating events, with *BRAF* seeming to be a promiscuous fusion partner.


Another new *BRAF* alteration was identified in ICGC_PA65, resulting in a three-amino-acid insertion (p.Arg506_insValLeuArg, insVLR)

in the interdomain cleft of *BRAF*—a structural region linked to *BRAF* activity¹⁷ and homodimerization¹⁸. Protein modeling predicted that the insertion of these residues stabilizes a dimeric form of *BRAF* (known to be active independent of RAS stimulation¹⁹) (**Fig. 1b**). Homodimerization was confirmed by immunoprecipitation, and the *BRAF*^{insVLR} mutant increased extracellular signal-regulated kinase (ERK) phosphorylation as effectively as the *BRAF*^{V600E} mutant (**Fig. 1c,d**).

New alterations in *KRAS* were also observed. ICGC_PA117 and ICGC_PA142 both showed two distinct mutations (encoding p.[Glu63Lys]+[Arg73Met] and p.[Leu19Phe]+[Gln22Lys], respectively). DNA and RNA sequencing data confirmed that both alterations affected the same allele (**Supplementary Fig. 4**). Although there are reports of double *KRAS* mutations in entities such as colon cancer²⁰, these typically involve at least one hotspot residue (codon 12, 13 or 61) and often represent heterogeneous tumor subclones rather than two hits in one allele (although this has also been described; for example, see ref. 21). The alterations identified in our tumors did not encompass classical mutational hotspots, suggesting that further characterization of downstream effects is warranted.

All but one of the cerebellar tumors in our series harbored a *BRAF* fusion, with this one exception having a *KRAS* alteration. Nine of 48 (19%) of the non-cerebellar tumors, however, lacked the above alterations. Further assessment of structural rearrangements identified two new gene fusions in a total of three samples, involving the region encoding the kinase domain of *NTRK2* (also known as *TrkB*)—an oncogene implicated in the tumorigenesis of neuroblastoma, among other cancers^{22,23}. The related *NTRK1* and *NTRK3* genes have previously been shown to be activated by fusion events (for example, *TPM3-NTRK1* in papillary thyroid cancer²⁴ and *ETV6-NTRK3* in multiple tumors²⁵). The *QKI-NTRK2* and *NACC2-NTRK2* fusions identified here were verified by PCR (**Fig. 2** and **Supplementary Fig. 3d**). Both 5' partners contained regions encoding dimerization domains and are therefore predicted to induce ligand-independent dimerization. Notably, N-terminal TrkB truncation has recently been shown to induce transformation of neural crest cells²⁶.

Figure 2 *NTRK2* is a new gene fusion target in pilocytic astrocytoma. Schematic of the *QKI-NTRK2* fusion gene in ICGC_PA159 resulting from a translocation between chromosomes 6 and 9. A similar fusion was observed in ICGC_PA82. The cDNA sequence at the fusion breakpoint (dashed line) and resulting exon and protein structures are shown. QUA1, Qua1 dimerization domain.



The downstream effects of TrkB activation are mediated, at least in part, via MAPK pathway activation²⁷.


A second new recurrent alteration, namely, mutation of two hotspots (codons for Asn546 and Lys656) within the kinase domain of *FGFR1*, was seen in five tumors (Fig. 3a and Supplementary Table 3). *FGFR1* is more commonly activated through amplification in tumors such as breast²⁸ and lung^{29,30} cancer. Occasional *FGFR1* mutations have been observed in adult glioblastoma (GBM)^{31,32}, a highly malignant astrocytoma, as have *FGFR1-TACC1* or *FGFR3-TACC3* fusion genes³³. Mutations in homologous codons in *FGFR2* and *FGFR3* are commonly found in other tumor types, particularly bladder, skin and endometrial cancers (see the Catalogue of Somatic Mutations in Cancer (COSMIC) database³⁴). Both mutations result in midbrain hyperproliferation in developing chick embryos³⁵. The p.Asn546Lys variant alters *FGFR1* autophosphorylation, resulting in higher kinase activity and transforming potential³⁶, whereas the p.Lys656Glu variant is also transforming *in vitro*³⁷. Notably, the latter study suggested that fibroblast growth factor 2 (FGF2, also known as bFGF) ligand was necessary in addition to *FGFR1* mutation to maintain neurosphere formation *in vitro*. Gene expression array data of 118 pilocytic astrocytomas, including 66 from the present series, showed significantly increased *FGF2* expression in pilocytic astrocytomas compared with 158 other astrocytic tumors^{38,39} or normal tissues⁴⁰. This increase was not restricted to only *FGFR1*-mutant or wild-type tumors, suggesting that ligand-mediated pathway activation may have a general role in tumorigenesis (Fig. 3b). Immunohistochemical detection of phosphorylated *FGFR1* showed strong, diffuse positivity in all seven pilocytic astrocytomas harboring an *FGFR1* mutation for which material was available. No positivity was observed in 11 tumors with wild-type *FGFR1*. All samples showed strong staining for phosphorylated ERK (Supplementary Fig. 5). Notably, ICGC_PA89 harbored an alternative alteration in *FGFR1* consisting of a ~4.5-kb internal tandem duplication (ITD) of the portion of the gene encoding the kinase domain, reminiscent of the activating internal tandem duplications of the *FLT3* kinase observed in acute myeloid leukemia⁴¹ (Fig. 3c).

Further recurrent mutations were found in the phosphatase gene *PTPN11* (also called *SHP-2*) encoding a RAS-MAPK-related adaptor protein (Fig. 3d). Both encoded alterations (p.Glu69Lys and p.Glu76Ala) were previously reported in juvenile monomyelocytic leukemia, which is frequently associated with *SHP-2* activation^{42,43}. Notably, both alterations were found in *FGFR1*-mutant tumors (ICGC_PA84 and ICGC_PA166), suggesting a cooperative role of these factors in tumorigenesis (Supplementary Table 3). Overexpression of mutant *SHP-2* alone did not elevate the levels of phosphorylated ERK *in vitro*, whereas the two *FGFR1* mutants, either alone or in combination with mutant *SHP-2*, upregulated the levels of phosphorylated ERK (Supplementary Fig. 6). This finding supports the hypothesis that *PTPN11* mutation alone is insufficient for pilocytic astrocytoma development but may have a modifying role in *FGFR1*-mutant tumors. Of note, *PTPN11* expression was higher in pilocytic astrocytomas compared with other astrocytomas or normal tissues (Fig. 3e), suggesting that this phosphatase has a broader role in the biology of this entity. An additional cohort of 45 non-cerebellar

pilocytic astrocytomas, negative for *KIAA1549-BRAF* fusion, was screened for *FGFR1* (exons 12 and 14) and *PTPN11* (exon 3) mutations. Nine cases harbored *FGFR1* mutations encoding a p.Asn546 or p.Lys656 alteration, and one additionally carried a *PTPN11* mutation encoding a p.Glu69Lys change (Supplementary Table 3), confirming our whole-genome sequencing findings. Germline *PTPN11* mutations are one of the causes of the hereditary developmental disorders Noonan syndrome⁴⁴ and multiple lentigines syndrome (also known as LEOPARD syndrome)⁴⁵. A few case reports have described pilocytic astrocytomas occurring in individuals with these syndromes^{46–49}. Thus, together with *NF1*, there are three known ‘RASopathies’, characterized by germline MAPK pathway mutations⁵⁰, linked with pilocytic astrocytoma tumorigenesis. In our germline sequencing data, however, *NF1* was the only RASopathy-related gene disrupted at a higher frequency than in the 1000 Genomes Project (see URLs).

Notably, all of the pilocytic astrocytomas in our cohort harbored a MAPK pathway alteration. *BRAF*, *FGFR1*, *KRAS* and *NF1* were the only genes found to be significantly mutated using the Genome MuSiC algorithm (see URLs; Supplementary Table 4). With the exception of *FGFR1* and *PTPN11*, each case typically harbored only one pathway alteration ($P < 0.0001$, permutation test; Fig. 4). Together with the finding that *BRAF* kinase activation alone is sufficient to induce pilocytic astrocytomas in mice^{51,52}, these data strongly support the concept of pilocytic astrocytoma as a prototypic single-pathway disease driven by a limited number of oncogenic hits (possibly only one in some cases; Supplementary Fig. 7).


One of the *FGFR1*-mutant tumors (ICGC_PA69) also had an *H3F3A* mutation encoding a p.Lys27Met alteration and somatic mutations of *NF1*—both of which are more commonly encountered in pediatric GBM⁵. Three experienced neuropathologists agreed on pilocytic astrocytoma histology for this case, although a diagnosis of GBM cannot be conclusively excluded, owing to limited material. By examining previous exome sequencing data for pediatric GBM⁵, we identified 3 of 48 samples (6%) with an *FGFR1* mutation. Notably, all three harbored the same constellation of an *H3F3A* p.Lys27Met alteration, a somatic *NF1* alteration and *FGFR1* activation (Supplementary Table 3). They were also wild type for *TP53*, which is mutated in most GBMs or diffuse intrinsic pontine gliomas^{5,53} with the *H3F3A* p.Lys27Met alteration. One tumor reported in a targeted sequencing cohort of medulloblastoma¹⁰ had a similar triple alteration,



with an H3F3A p.Lys27Met alteration, an NF1 alteration and an FGFR2 p.Lys659Glu alteration (homologous to FGFR1 p.Lys656Glu), making a total of five cases with this combination. Gene expression analysis indicated that this tumor was likely a GBM previously misclassified as medulloblastoma. It is not currently clear why these alterations occur in concert, and additional work will be required to assess their roles. One possibility is that *NF1* mutation may mimic elevated *PTPN11* expression, as activation of SHP-2 inhibits the recruitment of Ras GTPase-activating proteins (RasGAPs, including NF1) to the plasma membrane⁵⁴.

All *FGFR1*-mutant tumors were extracerebellar, mostly in midline locations (Supplementary Table 3), suggesting a link between cell of origin and/or microenvironment with *FGFR1*-driven tumorigenesis. The H3F3A p.Lys27Met alteration is also associated with midline GBM³⁹. Notably, *FGFR1* has a role in neural stem cell self-renewal⁵⁵ and is essential for midline glial cell development⁵⁶. This spatial clustering may also reflect differential sensitivity of distinct neural precursors to activating stimuli, particularly *NF1* loss^{57,58}. The type and timing of second hits (*H3F3A* or *NF1* mutation) and/or the differentiation stage of the cell of origin may contribute to determining a fate of oncogene-induced senescence and slow growth (pilocytic astrocytoma)^{59,60} versus aggressive malignancy with poor outcome (GBM).

In summary, this study has provided new insights into the tumorigenesis of pilocytic astrocytoma. Each tumor harbored very few mutations, in keeping with generally benign behavior. Our findings confirm the concept that pilocytic astrocytomas are predominantly



with an H3F3A p.Lys27Met alteration, an NF1 alteration and an FGFR2 p.Lys659Glu alteration (homologous to FGFR1 p.Lys656Glu), making a total of five cases with this combination. Gene expression analysis indicated that this tumor was likely a GBM previously misclassified as medulloblastoma. It is not currently clear why these alterations occur in concert, and additional work will be required to assess their roles. One possibility is that *NF1* mutation may mimic elevated *PTPN11* expression, as activation of SHP-2 inhibits the recruitment of Ras GTPase-activating proteins (RasGAPs, including NF1) to the plasma membrane⁵⁴.

driven by aberrant activation of the MAPK pathway. Most notably, however, we report new recurrent mutations in *NTRK2*, *FGFR1* and *PTPN11*, which were mutually exclusive with other RAF and RAS changes. Combined with the observation of *FGF2* and *PTPN11* over-expression, these results indicate upstream contributors to MAPK pathway activation in this entity. Emerging preclinical data suggest that BRAF inhibitors may trigger paradoxical activation in tumors harboring *KIAA1549-BRAF* fusions, that is, the majority of pilocytic astrocytomas⁶¹. Single-drug or combination therapy with FGFR, NTRK2 and/or MAPK/ERK kinase (MEK) inhibitors, several of which are currently in preclinical and clinical trials^{62–64}, may therefore represent rational treatment options. *BRAF*^{V600E}-specific agents may also be a logical choice for ~5% of patients. Finally, the identification of recurrent *FGFR1* mutations in a subset of pediatric GBMs provides an opportunity for the therapeutic targeting of FGFR signaling in these clinically challenging brain tumors.

URLs. ICGC PedBrain Tumor Project, <http://www.pedbraintumor.org/>; 1000 Genomes Project, <http://www.1000genomes.org/>; GenomeMuSiC, <http://gmt.genome.wustl.edu/genome-music/0.2/index.html>; Oncotator, <http://www.broadinstitute.org/oncotator/>; R2 tool, <http://r2.amc.nl>.

METHODS

Methods and any associated references are available in the [online version of the paper](#).

Accession code. Sequencing data have been deposited at the European Genome-phenome Archive, which is hosted by the European Bioinformatics Institute (EBI), under accession [EGAS00001000381](https://www.ebi.ac.uk/ena/record/EGAS00001000381).

Note: Supplementary information is available in the online version of the paper.

ACKNOWLEDGMENTS

For technical support and expertise, we thank B. Haase, D. Pavlinic and B. Baying (EMBL Genomics Core Facility); M. Wahlers and R. Lück (EMBL High-Performance Computing Facility); the DKFZ Genomics and Proteomics Core Facility; M. Knopf (NCT Heidelberg); K. Schlangen, M. Metsger, K. Schulz, A. Nürnberger, A. Kovacovics and M. Linser (Max Planck Institute for Molecular Genetics); S. Peetz-Dienhart and Y. Floer (University Hospital Münster); D.M. Pearson (University of Cambridge); and B. Huang, G. Zipprich, M. Heinold, R. Kabbe, A. Wittmann, L. Sieber and L. Linke (DKFZ). W. Stummer (Münster), B. Hoffmann (Münster), B. Rama (Osnabrück), H. Ebel (Hamm), H.A. Trost (Bayreuth) and U. Wildförster (Gelsenkirchen) provided detailed clinical information. We also thank GATC Biotech for sequencing services. This work was principally supported by the PedBrain Tumor Project contributing to the International Cancer Genome Consortium, funded by German Cancer Aid (109252) and by the German Federal Ministry of Education and Research (BMBF, grants 01KU1201A, MedSys 0315416C and NGFN^{plus} 01GS0883). Additional support came from the German Cancer Research Center–Heidelberg Center for Personalized Oncology (DKFZ-HIPO), the Max Planck Society, Genome Canada and the Canadian Institute for Health Research (CIHR) with cofunding from Genome BC, Génome Québec, CIHR-ICR (Institute for Cancer Research) and C17 (N. Jabado), Ian's Friend Foundation (M.A.K.), the US National Institutes of Health (NIH; grants RO1CA105607 and P30HD018655 to S.L.P.), the Dutch Cancer Foundations KWF (2010-4713) and KIKA (M.K.), the Brain Tumour Charity (S.R.L. and V.P.C.) and the Pediatric Low-Grade Astrocytoma Foundation (M.W.K. and K.L.L.).

AUTHOR CONTRIBUTIONS

D.T.W.J., S.R.L., D.A.K.Q., A.M.F., H.-J.W., A.M.S., S.H., M. Zuckermann, J.G., S. Schmidt, H.Ş.-C., H.W., S.B., E.P., S. Stark, B.R., D.F., C.C.B., C.v.K., P.v.S., R. Versteeg, M. Sultan, S.W., M.H. and J.F. performed and/or coordinated experimental work. B.H., N. Jäger, D.T.W.J., M.K., H.-J.W., T.Z., B.L., P.A.N., V.H., J.S., J.M., M. Zapatka, M. Schlesner, C.L.W., C.D.I., S.R., C.L., P.v.S., J.K., R. Volckmann and M. Ralsler performed data analysis. A.K., M. Ryzhova, C.M., B.W., A.U., C.H.-M., T.M., A.E.K., M.E., M.U.S., Y.-J.C., S.L.P., A.v.D., O.W., M.H., M.A.K., C.G.E., W.S., K.L.L., M.W.K., V.P.C. and N. Jabado collected data and

provided materials from study subject. D.T.W.J., B.H., N. Jäger, D.S., N. Jabado, R.E., P.L. and S.M.P. prepared the initial manuscript and figures. A.K., U.D.W., M.D.T., J.O.K., H.L., M.-L.Y., B.B., G.R., V.P.C., N. Jabado, R.E., P.L. and S.M.P. provided project leadership. All authors contributed to the final manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Central Brain Tumor Registry of the United States. *Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States, 2004–2008* (CBTRUS, Hinsdale, IL, 2012).
- Jones, D.T.W., Gronych, J., Lichter, P., Witt, O. & Pfister, S.M. MAPK pathway activation in pilocytic astrocytoma. *Cell Mol. Life Sci.* **69**, 1799–1811 (2012).
- Gnekow, A.K. *et al.* Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. *Neuro-oncol.* **14**, 1265–1284 (2012).
- Armstrong, G.T. *et al.* Survival and long-term health and cognitive outcomes after low-grade glioma. *Neuro-oncol.* **13**, 223–234 (2011).
- Schwartzentruber, J. *et al.* Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature* **482**, 226–231 (2012).
- Jones, D.T.W. *et al.* Tandem duplication producing a novel oncogenic *BRAF* fusion gene defines the majority of pilocytic astrocytomas. *Cancer Res.* **68**, 8673–8677 (2008).
- Jones, D.T.W. *et al.* Oncogenic *RAF1* rearrangement and a novel *BRAF* mutation as alternatives to *KIAA1549:BRAF* fusion in activating the MAPK pathway in pilocytic astrocytoma. *Oncogene* **28**, 2119–2123 (2009).
- Pfister, S. *et al.* *BRAF* gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. *J. Clin. Invest.* **118**, 1739–1749 (2008).
- Gutmann, D.H. *et al.* Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. *Genome Res.* **23**, 431–439 (2013).
- Jones, D.T.W. *et al.* Dissecting the genomic complexity underlying medulloblastoma. *Nature* **488**, 100–105 (2012).
- Pugh, T.J. *et al.* Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature* **488**, 106–110 (2012).
- Robinson, G. *et al.* Novel mutations target distinct subgroups of medulloblastoma. *Nature* **488**, 43–48 (2012).
- Downing, J.R. *et al.* The Pediatric Cancer Genome Project. *Nat. Genet.* **44**, 619–622 (2012).
- Stephens, P.J. *et al.* The landscape of cancer genes and mutational processes in breast cancer. *Nature* **486**, 400–404 (2012).
- Welch, J.S. *et al.* The origin and evolution of mutations in acute myeloid leukemia. *Cell* **150**, 264–278 (2012).
- Cin, H. *et al.* Oncogenic *FAM131B-BRAF* fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. *Acta Neuropathol.* **121**, 763–774 (2011).
- Wan, P.T. *et al.* Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell* **116**, 855–867 (2004).
- Rushworth, L.K., Hindley, A.D., O'Neill, E. & Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization. *Mol. Cell Biol.* **26**, 2262–2272 (2006).
- Terai, K. & Matsuda, M. The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. *EMBO J.* **25**, 3556–3564 (2006).
- Macedo, M.P. *et al.* Multiple mutations in the *Kras* gene in colorectal cancer: review of the literature with two case reports. *Int. J. Colorectal Dis.* **26**, 1241–1248 (2011).
- Naguib, A., Wilson, C.H., Adams, D.J. & Arends, M.J. Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. *J. Mol. Signal.* **6**, 2 (2011).
- Schramm, A. *et al.* Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. *Cancer Lett.* **228**, 143–153 (2005).
- Thiele, C.J., Li, Z. & McKee, A.E. On Trk—the TrkB signal transduction pathway is an increasingly important target in cancer biology. *Clin. Cancer Res.* **15**, 5962–5967 (2009).
- Greco, A., Miranda, C. & Pierotti, M.A. Rearrangements of *NTRK1* gene in papillary thyroid carcinoma. *Mol. Cell Endocrinol.* **321**, 44–49 (2010).
- Lannon, C.L. & Sorensen, P.H. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. *Semin. Cancer Biol.* **15**, 215–223 (2005).
- Dewitt, J. *et al.* Constitutively active TrkB confers an aggressive transformed phenotype to a neural crest-derived cell line. *Oncogene* published online; doi:10.1038/nc.2013.39 (4 March 2013).
- Kaplan, D.R. & Miller, F.D. Neurotrophin signal transduction in the nervous system. *Curr. Opin. Neurobiol.* **10**, 381–391 (2000).
- Theillet, C. *et al.* *FGFR1* and *PLAT* genes and DNA amplification at 8p12 in breast and ovarian cancers. *Genes Chromosom. Cancer* **7**, 219–226 (1993).
- Dutt, A. *et al.* Inhibitor-sensitive *FGFR1* amplification in human non-small cell lung cancer. *PLoS ONE* **6**, e20351 (2011).

30. Weiss, J. *et al.* Frequent and focal *FGFR1* amplification associates with therapeutically tractable *FGFR1* dependency in squamous cell lung cancer. *Sci. Transl. Med.* **2**, 62ra93 (2010).
31. Rand, V. *et al.* Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. *Proc. Natl. Acad. Sci. USA* **102**, 14344–14349 (2005).
32. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* **455**, 1061–1068 (2008).
33. Singh, D. *et al.* Transforming fusions of *FGFR* and *TACC* genes in human glioblastoma. *Science* **337**, 1231–1235 (2012).
34. Forbes, S.A. *et al.* COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res.* **39**, D945–D950 (2011).
35. Liu, A. *et al.* FGF17b and FGF18 have different midbrain regulatory properties from FGF8b or activated FGF receptors. *Development* **130**, 6175–6185 (2003).
36. Lew, E.D., Furdai, C.M., Anderson, K.S. & Schlessinger, J. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. *Sci. Signal.* **2**, ra6 (2009).
37. Yoon, K. *et al.* Fibroblast growth factor receptor signaling promotes radial glial identity and interacts with Notch1 signaling in telencephalic progenitors. *J. Neurosci.* **24**, 9497–9506 (2004).
38. Gravendeel, L.A. *et al.* Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. *Cancer Res.* **69**, 9065–9072 (2009).
39. Sturm, D. *et al.* Hotspot Mutations in *H3F3A* and *IDH1* define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell* **22**, 425–437 (2012).
40. Roth, R.B. *et al.* Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. *Neurogenetics* **7**, 67–80 (2006).
41. Breitenbuecher, F. *et al.* Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. *Blood* **113**, 4074–4077 (2009).
42. Tartaglia, M. *et al.* Somatic mutations in *PTPN11* in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. *Nat. Genet.* **34**, 148–150 (2003).
43. Chan, G., Kalaitzidis, D. & Neel, B. The tyrosine phosphatase Shp2 (*PTPN11*) in cancer. *Cancer Metastasis Rev.* **27**, 179–192 (2008).
44. Romano, A.A. *et al.* Noonan syndrome: clinical features, diagnosis, and management guidelines. *Pediatrics* **126**, 746–759 (2010).
45. Tartaglia, M. & Gelb, B.D. Noonan syndrome and related disorders: genetics and pathogenesis. *Annu. Rev. Genomics Hum. Genet.* **6**, 45–68 (2005).
46. Fryssira, H. *et al.* Tumor development in three patients with Noonan syndrome. *Eur. J. Pediatr.* **167**, 1025–1031 (2008).
47. Sanford, R.A., Bowman, R., Tomita, T., De Leon, G. & Palka, P. A 16-year-old male with Noonan's syndrome develops progressive scoliosis and deteriorating gait. *Pediatr. Neurosurg.* **30**, 47–52 (1999).
48. Schuettelpelz, L.G. *et al.* Pilocytic astrocytoma in a child with Noonan syndrome. *Pediatr. Blood Cancer* **53**, 1147–1149 (2009).
49. Vulpoi, C. *et al.* LEOPARD syndrome and pilocytic astrocytoma: a random association? *Endocrine Abstracts* **20**, 525 (2009).
50. Zenker, M. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors. *Curr. Opin. Pediatr.* **23**, 443–451 (2011).
51. Gronych, J. *et al.* An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. *J. Clin. Invest.* **121**, 1344–1348 (2011).
52. Kaul, A., Chen, Y.H., Emmett, R.J., Dahiya, S. & Gutmann, D.H. Pediatric glioma-associated *KIAA1549:BRAF* expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. *Genes Dev.* **26**, 2561–2566 (2012).
53. Khuong-Quang, D.A. *et al.* K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. *Acta Neuropathol.* **124**, 439–447 (2012).
54. Agazie, Y.M. & Hayman, M.J. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. *Mol. Cell Biol.* **23**, 7875–7886 (2003).
55. Ma, D.K., Ponnusamy, K., Song, M.R., Ming, G.L. & Song, H. Molecular genetic analysis of *FGFR1* signalling reveals distinct roles of MAPK and PLC γ 1 activation for self-renewal of adult neural stem cells. *Mol. Brain* **2**, 16 (2009).
56. Tole, S., Gutin, G., Bhatnagar, L., Remedios, R. & Hebert, J.M. Development of midline cell types and commissural axon tracts requires *Fgfr1* in the cerebrum. *Dev. Biol.* **289**, 141–151 (2006).
57. Lee, Y., Gianino, S.M. & Gutmann, D.H. Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. *Cancer Cell* **22**, 131–138 (2012).
58. Lee, Y., Yeh, T.H., Emmett, R.J., White, C.R. & Gutmann, D.H. Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. *Genes Dev.* **24**, 2317–2329 (2010).
59. Jacob, K. *et al.* Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. *Clin. Cancer Res.* **17**, 4650–4660 (2011).
60. Raabe, E.H. *et al.* BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. *Clin. Cancer Res.* **17**, 3590–3599 (2011).
61. Sievert, A.J. *et al.* Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. *Proc. Natl. Acad. Sci. USA* **110**, 5957–5962 (2013).
62. Dieci, M.V., Arnedos, M., Andre, F. & Soria, J.C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. *Cancer Discov.* **3**, 264–279 (2013).
63. Iyer, R. *et al.* AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts. *Cancer Chemother. Pharmacol.* **70**, 477–486 (2012).
64. Rusconi, P., Caiola, E. & Brogini, M. RAS/RAF/MEK inhibitors in oncology. *Curr. Med. Chem.* **19**, 1164–1176 (2012).

¹Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. ²Division of Theoretical Bioinformatics, DKFZ, Heidelberg, Germany. ³Department of Neuropathology, University of Heidelberg, Heidelberg, Germany. ⁴Clinical Cooperation Unit Neuropathology, DKFZ, Heidelberg, Germany. ⁵Max Planck Institute for Molecular Genetics, Berlin, Germany. ⁶Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. ⁷Department of Pathology, Division of Molecular Histopathology, University of Cambridge, Cambridge, UK. ⁸Department of Neuropathology, Burdenko Neurosurgical Institute, Moscow, Russia. ⁹Department of Human Genetics, McGill University, Montreal, Quebec, Canada. ¹⁰Division of Molecular Genetics, DKFZ, Heidelberg, Germany. ¹¹Genomics and Proteomics Core Facility, DKFZ, Heidelberg, Germany. ¹²Department of Pediatric Oncology, Hematology & Immunology, Heidelberg University Hospital, Heidelberg, Germany. ¹³McGill University and G enome Qu ebec Innovation Centre, Montreal, Quebec, Canada. ¹⁴Division of Translational Oncology, DKFZ and National Center for Tumor Diseases (NCT), Heidelberg, Germany. ¹⁵Heidelberg Center for Personalised Oncology (DKFZ-HIPO), Heidelberg, Germany. ¹⁶Institute for Pharmacy and Molecular Biotechnology (IPMB), University of Heidelberg, Heidelberg, Germany. ¹⁷BioQuant Center, University of Heidelberg, Heidelberg, Germany. ¹⁸Department of Oncogenomics, Amsterdam Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ¹⁹Department of Neuropathology, Institute of Pathology, W urzburg University, W urzburg, Germany. ²⁰Department of Pediatric Hematology and Oncology, Children's University Hospital W urzburg, W urzburg, Germany. ²¹Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany. ²²Clinical Cooperation Unit Pediatric Oncology, DKFZ, Heidelberg, Germany. ²³Department of Hematology and Oncology, Children's University Hospital, T ubingen, Germany. ²⁴Department of Neurosurgery, University Hospital, T ubingen, Germany. ²⁵Division of Child Neurology, Stanford University, Palo Alto, California, USA. ²⁶Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA. ²⁷Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. ²⁸Division of Neurosurgery, Hospital for Sick Children, Toronto, Ontario, Canada. ²⁹The Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, Ontario, Canada. ³⁰New York University (NYU) Langone Medical Center, Hassenfeld Children's Center for Cancer and Blood Disorders, New York, New York, USA. ³¹Division of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. ³²Cnopf'sche Kinderklinik, N urnberg Children's Hospital, N urnberg, Germany. ³³Institute of Neuropathology, University Hospital M unster, M unster, Germany. ³⁴Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. ³⁵Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA. ³⁶Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. ³⁷Department of Neuropathology, Heinrich-Heine-University D usseldorf, D usseldorf, Germany. ³⁸Department of Paediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada. ³⁹These authors contributed equally to this work. ⁴⁰These authors jointly directed this work. Correspondence should be addressed to R.E. (r.eils@dkfz-heidelberg.de), P.L. (m.macleod@dkfz-heidelberg.de) or S.M.P. (s.pfister@dkfz-heidelberg.de).

ONLINE METHODS

Sample collection. Informed consent and an ethical vote (Ethics Committee of the Medical Faculty of Heidelberg) were obtained according to ICGC guidelines. Tumor tissues were subjected to neuropathological review to confirm histology and tumor cell content.

DNA sequencing. Paired-end library preparation was conducted using Illumina v2 protocols. Genomic DNA (1–5 µg) was fragmented to an insert size of ~300 bp with a Covaris device, and size selection was performed using agarose gel excision. Mate-pair (long-range paired-end mapping) DNA library preparation was carried out using the v2 protocol from Illumina. Genomic DNA (10 µg) was fragmented to an insert size of 4.5 kb with a Hydroshear device, and size selection was performed. Deep sequencing was carried out with Illumina HiSeq 2000 instruments.

RNA sequencing. Twenty-three RNA sequencing libraries were prepared with purified polyA+ RNA fractions using strand-specific methods, following dUTP-based protocols as described⁶⁵, featuring cDNA fragmentation after mRNA priming with random hexamer (dN)₆ and oligo(dT) primers. Six libraries were constructed with a modified protocol whereby the polyA+ fraction was fragmented using RNA fragmentation reagents (Ambion, AM8740); first-strand synthesis was then performed with random hexamers only (cDNA fragmentation was omitted). Fifty RNA sequencing libraries were prepared with a ribosomal RNA-depleted fraction. In brief, 0.2 µg of total RNA was prepared using the RiboZero Gold kit (Epicentre). The resulting RNA was further processed following a previously described library preparation protocol⁶⁶, starting at the fragmentation step (step 2). Sequencing (2 × 51 bp) was carried out on the HiSeq 2000 platform.

Mapping and analysis. Sequencing reads were mapped and aligned to the hg19 reference assembly as previously described¹⁰, using Burrows-Wheeler Aligner (BWA)⁶⁷ (version 0.5), and were processed with SAMtools⁶⁸ (version 0.1.17) and Picard tools (version 1.61).

An in-house analysis pipeline based on SAMtools mpileup and bcftools⁶⁸ was used to detect SNVs and small indels. In addition to previously described filters to remove artifacts¹⁰, we excluded variants located in regions of low mappability or overlapping with the hiSeqDepthTop10Pct, Encode DAC Blacklisted Regions or Duke Excluded Regions tracks from the UCSC Genome Browser. High-confidence somatic SNVs were not allowed to overlap with any two of the following features: tandem repeats, simple repeats, low-complexity, satellite repeats or segmental duplications. In addition, the following heuristic criteria were required: (i) at least 5 tumor reads at the position; (ii) more than one variant read per strand or at least 5 variant reads in total and variant allele fraction of >0.1; (iii) at least 12 reads at the position in the matching control; (iv) less than 1 of 30 of the control reads supporting the variant; (v) less than 300 reads at the corresponding position in the control; and (vi) no non-reference, non-variant bases at the corresponding position in the control.

Indels were called with SAMtools mpileup and bcftools on reads with mapping quality of >20 and were scored in a similar way as SNVs. Overlap with tandem or simple repeats, however, was not penalized, as these elements are prone to indels owing to polymerase slippage. Because indel alignments in the matched control can be slightly shifted in comparison to the tumor or mismatches can be preferred over gaps, germline events can be falsely called as somatic. We therefore required not more than one mismatch or indel in the matching control within 20 bp of the indel identified in the tumor.

Tumor and matched control samples were also analyzed with Pindel (version 0.2.4h)⁶⁹. Events in the tumor were only considered when supported by at least five reads and if the number of supporting reads divided by the maximum read depth at the left and right breakpoints was >0.05. The matched control sample was also analyzed by SAMtools mpileup at tumor indel positions and 10 bp up- and downstream of this position. Variants were classified as somatic if both Pindel and SAMtools mpileup did not call a multibase variant in the control sample. Only additional indels in RASopathy genes were reported from the Pindel analysis (owing to a high false positive rate); all other indels were called with SAMtools as described.

SNVs and indels were functionally annotated with RefSeq gene annotations using ANNOVAR⁷⁰ and Oncotator. For the identification of significantly

mutated genes, we used high-confidence somatic SNVs and indels as input for Genome MuSiC⁷¹ (version 0.3), setting max-fdr to 0.05 in the genome music smg module. Substitution patterns of SNVs were evaluated in a sequence context of all 96 possible trinucleotides to assess mutational signatures⁷².

Integration of SNVs and indels with RNA sequencing data. Gene expression levels were calculated per exon according to reads per kilobase of exon model per million mapped reads (RPKM) using BEDTools⁷³ and custom Perl scripts. Where available, candidate DNA variant positions were annotated with RNA information by generating a pileup of the DNA variant position in the RNA BAM file (**Supplementary Table 2**).

Structural rearrangement detection and verification. Rearrangements identified on the basis of paired-end data were detected using read-depth analysis, CREST⁷⁴, DELLY⁷⁵ and manual inspection of sequencing reads. Rearrangements identified on the basis of mate-pair data were detected using DELLY and manual inspection of sequencing reads, as previously described¹⁰.

Structural variants were verified by PCR (details on conditions and primer sequences available upon request). PCR products were sent to GATC Biotech (Germany) for Sanger sequencing to confirm breakpoints.

Fusion transcript detection and verification. Fastq files from transcriptome sequencing were used for *de novo* annotation of fusion transcripts using the TopHat-Fusion⁷⁶ and deFuse⁷⁷ algorithms with standard parameters. Where neither algorithm detected fusions but whole-genome sequencing supported the presence of a fusion, we extracted corresponding transcriptome reads matching the theoretical sequence surrounding the predicted fusion border and then counted as fusion reads those where the entire 51-bp sequence was derived from the predicted fused exons.

Primers for the amplification of neighboring exons in normal (unfused) transcripts were tested in RT-PCR using total RNA from normal cerebellum (BioChain, lot B307003). Validated primers were used to amplify the normal transcripts (control) and fusion transcripts from tumor RNA using the SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase (Invitrogen). Details on PCR conditions and primer sequences are available upon request.

Computational protein modeling. A dimeric model of mutant BRAF^{FinsVLR} was produced with Modeller⁷⁸ using the PDB structure 4E26 as a template. Ten models were produced, with the one having the lowest discrete optimized protein energy (DOPE) score shown in **Figure 1b**.

Expression array analysis. Affymetrix U133 Plus 2.0 expression array data for genes of interest were extracted from publicly available data sets via the R2 software tool and for additional cases on an early-access basis through collaboration with the Microarray Department of the University of Amsterdam. The MAS5.0 algorithm of the GCOS program (Affymetrix) was used for normalization and the assignment of detection *P* values. Array quality was ensured by inspection of *ACTB* and *GAPDH* 5'-3' ratios as well as the percentage of present calls.

Verification of SNVs and indels. All SNVs and indels in *FGFR1*, *PTPN11*, *BRAF*, *KRAS*, *NF1* and *H3F3A* were verified by PCR followed by capillary (Sanger) sequencing. Additional variants were also verified in this way, as listed in **Supplementary Table 2**. The verification rate for SNVs was >98% and for indels was >70%. Alterations determined to be false are not included in **Supplementary Table 2**.

In vitro and protein assays. Coding sequences of *BRAF*, *PTPN11* and *FGFR1* were cloned from normal brain cDNA (Stratagene) into a pcDNA3.1 vector encoding HA, Flag or AU1 epitope tags. Site-directed mutagenesis (QuikChangeII XL, Agilent Technologies) was used to generate constructs encoding BRAF^{V600E}, BRAF^{FinsVLR}, SHP-2^{E69K}, SHP-2^{E76A}, FGFR1^{N546K} and FGFR1^{K656E}.

NIH3T3 mouse fibroblasts (Leibniz Institute German Collection of Microorganisms and Cell Cultures (DSMZ); mycoplasma tested) were cultured

in DMEM (Life Technologies) supplemented with 10% FBS (Life Technologies) and penicillin-streptomycin at 37 °C in 5% CO₂. Cells were transfected using Lipofectamine 2000 diluted in Opti-MEM (Invitrogen) and switched to serum-free DMEM 24 h after transfection. After a further 24 h, cells were lysed in either RIPA buffer or RLT buffer (Qiagen). Protein electrophoresis was performed using 4–12% gradient NuPAGE Bis-Tris Precast Gels (Life Technologies) with transfer to a PVDF membrane. Antibodies for protein blotting, with detection using ECL (GE Healthcare Life Sciences), were as follows: antibody to ERK1/2 (rabbit polyclonal, Cell Signaling Technology, 9102), antibody to phosphorylated ERK1/2 (rabbit monoclonal 20G11, Cell Signaling Technology, 4376), antibody to HA (rabbit monoclonal C29F4, Cell Signaling Technology, 3724), antibody to AU1 (rabbit polyclonal, Abcam, ab3401), antibody to DYKDDDDK (Flag) (rabbit polyclonal, Cell Signaling Technology, 2368), HRP-conjugated goat antibody to rabbit immunoglobulin G (IgG) (Santa Cruz Biotechnology, sc-2004) and HRP-conjugated goat antibody to mouse immunoglobulin (Santa Cruz Biotechnology, sc-2005). All primary antibodies were used at a dilution of 1:2,000.

For coimmunoprecipitation experiments to assess BRAF dimerization, cells were washed twice in ice-cold PBS, scraped, pelleted and then lysed on ice in five pellet volumes of lysis buffer (50 mM HEPES, pH 7.5, 250 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 10% glycerol, 0.1% Triton X-100 and protease inhibitors) with regular vortexing. Lysates were run through a QiaShredder column (Qiagen), centrifuged and transferred to a new tube. Anti-HA agarose slurry (8 µl; Thermo Scientific) was washed three times and then resuspended in 20 µl of lysis buffer. Protein extract (50 µg) was added to the anti-HA slurry and rotated overnight at 4 °C. Finally, beads were pelleted, washed seven times in lysis buffer and resuspended in SDS sample buffer for protein blotting.

Immunohistochemistry. Immunohistochemistry was performed with an automated stainer (Benchmark XT, Ventana). Phosphorylated FGFR (Tyr653/

Tyr654) was detected using antibody PA5-12594 (Thermo Scientific) diluted 1:50. Phosphorylated ERK1/2 (Thr202/Tyr204) was detected using antibody 9101 (Cell Signaling Technology) diluted 1:100.

65. Parkhomchuk, D. *et al.* Transcriptome analysis by strand-specific sequencing of complementary DNA. *Nucleic Acids Res.* **37**, e123 (2009).
66. Sultan, M. *et al.* A simple strand-specific RNA-Seq library preparation protocol combining the Illumina TruSeq RNA and the dUTP methods. *Biochem. Biophys. Res. Commun.* **422**, 643–646 (2012).
67. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).
68. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
69. Ye, K., Schulz, M.H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. *Bioinformatics* **25**, 2865–2871 (2009).
70. Wang, K. *et al.* ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164 (2010).
71. Dees, N.D. *et al.* MuSiC: identifying mutational significance in cancer genomes. *Genome Res.* **22**, 1589–1598 (2012).
72. Nik-Zainal, S. *et al.* Mutational processes molding the genomes of 21 breast cancers. *Cell* **149**, 979–993 (2012).
73. Quinlan, A.R. & Hall, I.M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842 (2010).
74. Wang, J. *et al.* CREST maps somatic structural variation in cancer genomes with base-pair resolution. *Nat. Methods* **8**, 652–654 (2011).
75. Rausch, T. *et al.* DELLY: structural variant discovery by integrated paired-end and split-read analysis. *Bioinformatics* **28**, i333–i339 (2012).
76. Kim, D. & Salzberg, S.L. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. *Genome Biol.* **12**, R72 (2011).
77. McPherson, A. *et al.* deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. *PLoS Comput. Biol.* **7**, e1001138 (2011).
78. Sali, A. & Blundell, T.L. Comparative protein modelling by satisfaction of spatial restraints. *J. Mol. Biol.* **234**, 779–815 (1993).